Skip to main content
. 2015 Jan 26;33(7):723–731. doi: 10.1200/JCO.2014.56.5119

Fig 4.

Fig 4.

Waterfall plots of prostate-specific antigen (PSA) response at 12 weeks in the evaluable patients with baseline and postbaseline assessments in the (A) orteronel-prednisone group (n = 559) and the (B) placebo-prednisone group (n = 283). Plots are truncated at 200%.